ADLM 2026

Date: July 28, 2026 - July 30, 2026
Type: In-person
Location: North America
Areas of Interest: Hereditary Disorders, Oncology

One workflow, entirely in-house.

Most lab leaders arrive at ADLM with the same question: how do we bring NGS in-house, or scale what we already run, without adding headcount, cost, or turnaround time?

At Booth #1172, the AVITI24 system and the SOPHiA DDM™ Platform’s AI-powered analysis run as one connected workflow. Your lab sequences and interprets its own data, and your data stays in-house.

780+ institutions run SOPHiA DDM™ today
70+ countries, standardizing and scaling NGS workflows

Stop by Booth #1172, wherever your lab is.
Tell us where you are, and we’ll tailor the conversation.

Booth #1172 hours:
Tue Jul 28, 9:30 AM–5:00 PM
Wed Jul 29, 9:30 AM–5:00 PM
Thu Jul 30, 9:30 AM–12:00 PM

Launching an NGS program

See how to stand up sequencing and analysis together, without building a bioinformatics team from scratch.

Running an established program

See where SOPHiA DDM™ removes the bottlenecks you already feel: variant interpretation time, workflow standardization, and QC overhead.

Weighing in-house economics

Walk through the cost and turnaround math labs are using to build the business case for in-house testing.

Whether you’re evaluating NGS solutions, expanding your test menu, or exploring how AI can strengthen your genomic pipeline, our teams are ready to talk.

Book 15 minutes with our team now, or simply stop by and say hello. See you in Anaheim.

Book a Meeting

URL

This field is for validation purposes and should be left unchanged.

First Name(Required)

Last Name(Required)

Institution(Required)

Job Title(Required)

Area of Interest(Required)

Email(Required)

Phone

Country(Required)

Select US State(Required)

Privacy Policy(Required)

By checking this box, I declare that I have read and accepted in full SOPHiA GENETICS privacy policy. The data provided herein is used to process your request. Click here for more information relating to our privacy policy

Marketing Opt-In

I agree to receive information from SOPHiA GENETICS about products, services, events and promotions. I understand I will be able unsubscribe by using the link integrated with the communication at any time.

3rd Party Opt-In

I agree that SOPHiA GENETICS may share my webinar registration details with 3rd parties, and that I may receive marketing communications from these 3rd parties. I understand that I can withdraw my consent at any time.

This field is hidden when viewing the form

Job Title/Industry(Required)

CAPTCHA

Disclaimer notice:
The term SOPHIA used by the speaker refers to SOPHiA GENETICS and its products.
The opinions expressed during this presentation are these of the speaker and may not represent the opinions of SOPHiA GENETICS.
SOPHiA GENETICS does not provide support in the validation of custom products for clinical use.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.

SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.

All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.

SOPHiA DDM™ Overview

SOPHiA DDM™ for Genomics

SOPHiA DDM™ for Radiomics

SOPHiA DDM™ for Multimodal

Professional Services